Abstract
Glioblastoma (GBM) is the most common type of primary malignant brain tumor. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor. Accordingly, recent studies have been focused on the aberrant signal transduction pathways in glioblastoma. Many patient derived primary glioblastomas and cell lines express constitutively activated signal transducers and activators of transcription 3 (STAT3). Here we focused on the recent progresses regarding to the roles of STAT3 in glioblastoma and glioblastoma stem cells (GBM-SCs), the dysregulation of STAT3 in glioblastoma, and targeting STAT3 for glioblastoma therapy.
Keywords: Cytokine, glioblastoma, glioblastoma stem cells, growth factor, STAT3, STAT3 inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title: STAT3 as a Therapeutic Target for Glioblastoma
Volume: 10 Issue: 7
Author(s): Yan Liu, Chenglong Li and Jiayuh Lin
Affiliation:
Keywords: Cytokine, glioblastoma, glioblastoma stem cells, growth factor, STAT3, STAT3 inhibitor.
Abstract: Glioblastoma (GBM) is the most common type of primary malignant brain tumor. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor. Accordingly, recent studies have been focused on the aberrant signal transduction pathways in glioblastoma. Many patient derived primary glioblastomas and cell lines express constitutively activated signal transducers and activators of transcription 3 (STAT3). Here we focused on the recent progresses regarding to the roles of STAT3 in glioblastoma and glioblastoma stem cells (GBM-SCs), the dysregulation of STAT3 in glioblastoma, and targeting STAT3 for glioblastoma therapy.
Export Options
About this article
Cite this article as:
Liu Yan, Li Chenglong and Lin Jiayuh, STAT3 as a Therapeutic Target for Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (7) . https://dx.doi.org/10.2174/187152010793498636
DOI https://dx.doi.org/10.2174/187152010793498636 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism The Role of H. pylori Infection in Diabetes
Current Diabetes Reviews The Status of Disease Registries in the United States: Reflections
Applied Clinical Research, Clinical Trials and Regulatory Affairs A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer
Current Cancer Drug Targets Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Identification of New Pancreatic Beta Cell Targets for In Vivo Imaging by a Systems Biology Approach
Current Pharmaceutical Design Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design HSP60 as a Drug Target
Current Pharmaceutical Design In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP
Current Cancer Drug Targets Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design